Amphera

Amphera B.V. is a clinical-stage biotechnology company dedicated to developing dendritic cell therapies for cancer treatment. MesoPher consists of autologous dendritic cells loaded with our proprietary allogeneic tumor cell lysate, PheraLys. PheraLys is an innovative and well-characterized source of broad-spectrum tumor-associated antigens. Several clinical studies on our lead candidate, MesoPher, are currently underway.